Human leishmaniasis is a vectorborne disease occurring mostly in Central and South America, the Europe/Africa Mediterranean area, the Middle East, and the Indian subcontinent. This disease is caused by parasites in the *Leishmania* subgenera *Viannia* and *Leishmania*, affects ≈2.5 million persons, and causes 60,000 deaths yearly worldwide (1). The disease has 3 main clinical forms: cutaneous leishmaniasis (CL), the most prevalent form and caused by species in both *Viannia* and *Leishmania* subgenera; mucocutaneous leishmaniasis, caused by species in the subgenus *Viannia*; and visceral leishmaniasis, caused by *L. (L.) donovani* and *L. (L.) infantum*. These syndromes might lead to social stigma because of permanent scars, skin disfigurement, and partial/total destruction of oral/nasopharyngeal mucosa and can result in systemic symptoms including splenomegaly, wasting, and even death (2).

Species-specific *Leishmania* identification is critical in clinical management and epidemiologic investigations (2). Detection and identification of *Leishmania* parasites were traditionally done through microscopic and multilocus enzyme electrophoresis analysis. Currently, PCR-based methods and multilocus DNA sequence analyses (MLSA) combined with next-generation sequencing, have improved phylogenetic resolution and provided insights into parasite identification, classification, genetic polymorphism, virulence, and drug resistance (3,4).

*Leishmania* parasites are emerging in previously nonendemic areas (5); traditional and exotic *Leishmania* species/strains have been reported in focal areas of the Americas, Europe, Africa, Asia, and the Western Pacific (6). In the United States, leishmaniasis is mostly nonreportable and historically considered a travel-associated disease. However, the activity of natural vectors of *Leishmania* and occurrence of autochthonous zoonotic cases of CL and visceral leishmaniasis caused by *L. (L.) mexicana* or *L. (L.) infantum* have been reported in several states, including Alabama, Arizona, Arkansas, Delaware, Georgia, Kentucky, Louisiana, Maryland, Mississippi, Ohio, Oklahoma, South Carolina, and Texas (7–10). Those reports suggest the possibility of local transmission of leishmaniasis, especially in the southwestern US region. We report an autochthonous case of CL from Arizona, USA, caused by an unknown parasite in the subgenus *Leishmania*.

**The Study**

In December 2017, a 72-year-old woman from Pima County, Arizona, sought medical care for 2 discrete, progressive, edematous, violaceous papular lesions on the low back. The patient had a history of granulomatosis with polyangiitis, chronic sinusitis, chronic kidney disease, and pulmonary coccidioidomycosis. The patient had never traveled internationally and did not have an underlying health condition predisposing her to leishmaniasis.

We investigated an autochthonous case of cutaneous leishmaniasis caused by a genetically different *Leishmania* sp. in a patient in Arizona, USA. This parasite was classified into the subgenus *Leishmania* on the basis of multilocus DNA sequence and phylogenetic analyses of the rRNA locus and 11 reference genes.

**Author affiliations:** Centers for Disease Control and Prevention, Atlanta, Georgia, USA (M. de Almeida, Y. Zheng, F.S. Nascimento, H. Bishop, V.A. Cama, D. Batra, Y. Unoarumhi, E.W. Liu); Eagle Global Scientific, San Antonio, Texas, USA (Y. Zheng); University of Arizona College of Medicine, Tucson, Arizona, USA (A.K. Afghan, V.Y. Shi, F.M. Donovan); University of California, San Francisco, California, USA (P.E. LeBoit)

DOI: https://doi.org/10.3201/eid2706.204198
In January 2018, after a third lesion erupted, we performed skin biopsies. Histologic sections showed non-necrotizing granulomas in the papillary dermis, and tiny, basophilic, spherical inclusions within histiocyte cytoplasm resembling amastigotes, suggestive of CL. The lesions showed a limited extent and spontaneous improvement; therefore, no specific treatment was prescribed. The patient was followed for almost 2 years, and the 3 skin lesions remained nodular without ulceration, which eventually resolved by December 2019. The patient remained otherwise asymptomatic.

We tested clinical specimens from the patient following the Centers for Disease Control and Prevention (CDC)–approved protocol for using residual specimens from human subjects (use of residual diagnostic specimens from humans for laboratory methods research protocol no. 6756). We used lesion biopsy specimens submitted to CDC for DNA extraction, touch-prep smears, and in vitro culture in Roswell Park Memorial Institute medium (GIBCO-Thermo-Fisher, https://www.thermofisher.com) containing 15% fetal bovine serum at 25°C (11). Microscopic analysis of touch-prep smears identified a large number of amastigotes, whereas promastigotes with cellular shape and architecture compatible with species in the subgenus *Leishmania* were observed from culture (Figure 1).

We extracted DNA from biopsy specimens, cultured parasites by using the DNeasy Blood and Tissue Kit (QIAGEN, https://www.qiagen.com), and amplified the internal transcribed spacer 2 (ITS2) locus by using PCR. We then Sanger sequenced amplicons bidirectionally, assembled by using Lasergene Seqman Pro Software (DNASTAR, Inc., https://www.dnastar.com), and compared with sequences in the GenBank database by using BLASTn (https://blast.ncbi.nlm.nih.gov/Blast.cgi) (11). The resulting sequence (380 bp) (GenBank accession no. MT764332) had low similarity with *L. (L.) donovani* HQ830358 (90.36%), *L. (L.) infantum* AJ 634370 (89.9%), *Leishmania* sp. FM209179 (89.5%), *L. (L.) tropica* FJ948457 (89.2%), *L. (L.) mexicana* FJ948437 (85.1%), and species in the subgenus *Viannia* (<80.0%). We also tested DNA samples for amplicon melting temperature by using a SYBR green real-time, quantitative PCR protocol, which enables presumptive discrimination of *Leishmania* species (12). This analysis showed a melting temperature of 79.5°C, indicating *L. (L.) infantum* infection. On the basis of PCR analysis, the case-patient was identified as being infected with a *Leishmania* spp., without providing species-level identification.

We used DNA extracted from cultured parasites by using the MagAttract HMW DNA Kit (QIAGEN) to prepare genomic libraries by using the NEBNext Ultra II DNA Library Prep (New England Biolabs, https://www.neb.com) and subjected them to whole-genome sequencing by using the MiSeq platform (Illumina, https://www.illumina.com). MiSeq sequencing resulted in 22,808,630 *Leishmania* reads that had >100× coverage, 3,464 contigs of 29,491,421 bp, and a GC content of 59.68%.

We conducted MLSA by comparing open reading frames (ORFs) of MiSeq data against GenBank reference sequences at the following loci: β-actin, aspartate aminotransferase, cytosolic glyceraldehyde-3-phosphate dehydrogenase, glucose-6-phosphate dehydrogenase, glucose-6-phosphate isomerase, isocitrate dehydrogenase, cytosolic nicotinamide adenine dinucleotide phosphate, malic enzyme, mannose phosphate isomerase, 6-phosphogluconate dehydrogenase, 6-phosphoglucomutase, heat-shock protein 70, 18S rRNA ITS region and rRNA. We determined similarities between MiSeq and database ORFs, fragment length, and GenBank accession no. (Table, https://wwwnc.cdc.gov/EID/article/27/6/20-4198-T1.htm). Similarities to *Viannia* reference sequences were 99.6% for 18S rRNA and 65.23% for ITS rRNA loci. To visualize the taxonomic location of the isolate from Arizona, we constructed an evolutionary distance tree by using MiSeq 18S rRNA and cytosolic glyceraldehyde-3-phosphate dehydrogenase ORFs, as well as complete reference sequences in the subgenera *Leishmania*, *Viannia*, and *Mundina* (Figure 2).
Conclusions

Leishmania species associated with human clinical cases are typically prevalent in tropical and subtropical foci and classified into 2 subgenera: Viannia and Leishmania. Nonetheless, environmental changes might contribute to expansion of natural vectors, reservoirs, and emergence of novel Leishmania strains and leishmaniasis in nonendemic areas, posing a new and serious challenge to public health (5,6).

We report an autochthonous case of CL caused by a previously undescribed Leishmania parasite in a patient in Arizona. The integrated interpretation of the clinical information, travel history, parasite morphology, CDC species-specific diagnostic test results, and MLSA/phylogenetic analyses suggest that the isolate from Arizona could be a new strain or species within the subgenus Leishmania. This isolate is also genetically distinct at the internal transcribed spacer 2 locus from reported isolates for 18 previous cases of leishmaniasis from Arizona, characterized by CDC over the past 10 years, which were detected in travelers returning from disease-endemic areas.

Figure 2. Phylogenetic tree of Leishmania subgenus isolates from a patient in Arizona, USA, and reference Leishmania species in relationship to species in the subgenera Leishmania, Viannia, and Mundina. A) Phylogenetic tree of Leishmania 18S rRNA genes. Sequences of Crithidia fasciculata and Leptomonas seymouri are included as references. L. (V.) panamensis (GenBank accession no. GQ332362); L. (V.) braziliensis (accession no. GQ332355); L. (L.) mexicana (accession no. GQ332260); L. (L.) infantum (accession no. GQ332359); L. (L.) donovani (accession no. GQ332356); L. (M.) martiniquensis (accession no. AF303938); L. (M.) enriettii (accession no. ATAF02000704); Leptomonas seymore (accession no. KP717894); and Crithidia fasciculata (accession no. Y00055). The 2 non-Leishmania trypanosomatids (Leptomonas seymore and Crithidia fasciculata) were included in the phylogenetic tree because they were previously described as co-infecting parasites in human leishmaniasis cases. B) Phylogenetic tree of glyceraldehyde-3-phosphate dehydrogenase genes. Sequences from Crithidia fasciculata and Leptomonas seymouri were included as references. Numbers along branches indicate bootstrap values. Scale bars indicate nucleotide substitutions per site.
Despite these findings, we realize that classification of this parasite cannot be conclusively determined based solely on genetic evidence observed in this study. Therefore, further investigations (including multilocus enzyme electrophoresis and whole-genome sequencing with next-generation sequencing long read fragments) will be needed to confirm whether the isolate from Arizona is a new species or a new strain in the subgenus *Leishmania*.

Historically, human leishmaniasis in the United States has been considered an exotic, travel-acquired infection. However, this concept must be reexamined because of the expansion of sylvatic animal reservoirs and natural sand fly vectors of *Leishmania* spp. and reports of human and animal autochthonous cases in several states (7–9,13–15). Considering the patient’s travel history, the increased reports of zoonotic cases, and the active presence of sand fly vectors/reservoirs in southern areas of the United States, we concluded that the CL reported was probably caused by local parasite transmission. Because there is increasing evidence of likely local transmission, leishmaniasis could be emerging in the southwestern United States.

**Acknowledgments**
We thank the patient for participating in the study and Sara Sapp and Joel Barret for providing invaluable assistance with illustration preparation and manuscript review.

**About the Author**
Dr. Marcos de Almeida is a research molecular biologist in the Division of Parasitic Diseases and Malaria, Center for Global Health, Centers for Disease Control and Prevention, Atlanta, GA. His primary research interests are developing diagnostic tests for several parasites of public health concern and leishmaniasis diagnostics.

**References**
1. Alvar J, Vélez ID, Bern C, Herrero M, Desjeux P, Cano J, et al.; WHO Leishmaniasis Control Team. Leishmaniasis worldwide and global estimates of its incidence. PLoS One. 2012;7:e35671. https://doi.org/10.1371/journal.pone.0035671
2. Herwaldt BL. Leishmaniasis. Lancet. 1999;354:1191–9. https://doi.org/10.1016/S0140-6736(98)01078-2
3. Glaeser SP, Kämper P. Multilocus sequence analysis (MLSA) in prokaryotic taxonomy. Syst Appl Microbiol. 2015;38:237–45. https://doi.org/10.1016/j.syapm.2015.03.007
4. Schönian G, Kuhls K, Mauricio IL. Molecular approaches for a better understanding of the epidemiology and population genetics of *Leishmania*. Parasitology. 2011;138:405–25. https://doi.org/10.1017/S0031182010001538
5. González C, Wang O, Strutz SE, González-Salazar C, Sánchez-Cordero V, Sarkar S. Climate change and risk of leishmaniasis in North America: predictions from ecological niche models of vector and reservoir species. PLoS Negl Trop Dis. 2010;4:e385. https://doi.org/10.1371/journal.pntd.0000385
6. Sereno D. *Leishmania* (*Mundinia*) spp.: from description to emergence as new human and animal *Leishmania* pathogens. New Microbes New Infect. 2019;30:100540. https://doi.org/10.1016/j.nmni.2019.100540
7. Douvoyiannis M, Khromachou T, Byers N, Hargreaves J, Murray HW. Cutaneous leishmaniasis in North Dakota. Clin Infect Dis. 2014;59:e73–5. https://doi.org/10.1093/cid/ciu386
8. Kipp EJ, de Almeida M, Marpel CT, Bradbury RS, Benedict TK, Lin W, et al. An atypical case of autochthonous cutaneous leishmaniasis associated with naturally infected phlebotomine sand flies in Texas, United States. Am J Trop Med Hyg. 2020;103:2496–501. https://doi.org/10.4269/ajtmh.20-0107
9. McIlwee BE, Weis SE, Hosler GA. Incidence of endemic human cutaneous leishmaniasis in the United States. JAMA Dermatol. 2018;154:1032–9. https://doi.org/10.1001/jamadermatol.2018.2133
10. de Almeida ME, Spann DR, Bradbury RS. *Leishmania infantum* in US-born dog. Emerg Infect Dis. 2020;26:1882–4. https://doi.org/10.3201/eid2608.200149
11. de Almeida ME, Steurer FJ, Koru O, Herwaldt BL, Pieniazek NJ, da Silva AJ. Identification of *Leishmania* spp. by molecular amplification and DNA sequencing analysis of a fragment of RNA internal transcribed spacer 2. J Clin Microbiol. 2011;49:3143–9. https://doi.org/10.1128/JCM.01177-11
12. de Almeida ME, Koru O, Steurer F, Herwaldt BL, da Silva AJ. Detection and differentiation of *Leishmania* spp. in clinical specimens by use of a SYBR green-based real-time PCR assay. J Clin Microbiol. 2016;55:281–90. https://doi.org/10.1128/JCM.01764-16
13. Clarke CF, Bradley KK, Wright JH, Glowicz J. Case report: emergence of autochthonous cutaneous leishmaniasis in northeastern Texas and southeastern Oklahoma. Am J Trop Med Hyg. 2013;88:157–61. https://doi.org/10.4269/ajtmh.2012.11-0717
14. Petersen CA, Barr SC. Canine leishmaniasis in North America: emerging or newly recognized? Vet Clin North Am Small Anim Pract. 2009;39:1065–74, vii. https://doi.org/10.1016/j.cvsm.2009.06.008
15. Schaut RG, Robles-Murguia M, Juelsgaard R, Esch KJ, Bartholomay LC, Ramalho-Ortigao M, et al. Vectorborne transmission of *Leishmania infantum* from hounds, United States. Emerg Infect Dis. 2015;21:2209–12. https://doi.org/10.3201/eid2112.141167

Address for correspondence: Marcos de Almeida, Centers for Disease Control and Prevention, 1600 Clifton Rd NE, Mailstop H23–9, Atlanta, GA 30329-4027, USA; email: bnz0@cdc.gov